Post Hoc Exploratory Analysis Of Two Phase 2 Trials Of Quizartinib Monotherapy In Patients (Pts) With Flt3-Itd-Mutated (Mu) Relapsed/Refractory (R/R) Aml With Or Without Prior 1st-Generation Flt3 Tyrosine Kinase Inhibitors (Tki) Treatment.
JOURNAL OF CLINICAL ONCOLOGY（2018）
Abstract
7017Background: First-generation (1st gen) FLT3 TKIs such as sorafenib (SOR) / midostaurin (M) are increasingly used for treatment of FLT3-mu acute myeloid leukemia (AML). Quizartinib (Q) is a high...
MoreTranslated text
Key words
quizartinib monotherapy,treatment,inhibitors,st-generation
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined